blue cross blue shield semaglutide Drops Coverage of GLP-1 Obesity Drugs Most on Wegovy and Saxenda

The boom in compounded semaglutide when brand prices were higher and Eli Lillys push to offer Zepbound vials through lower priced self-pay channels both point in the same direction: when GLP-1 prices fall in cash-pay settings, demand responds quickly

Many of the same substances are used as PHARMACEUTIC AIDS

Speaking to reporters in mid-June, state Senate Majority Leader Joe Pittman (R., Indiana) said that addressing rising Medicaid costs was a fundamental pillar of budget talks, and that absent any constraints on those costs growth, there's not going to be a lot to talk about. While Youre Here For his caucus, the coverage reduction is a key victory

-